12:00 PM EST, 12/05/2024 (MT Newswires) -- Mind Medicine (MNMD) said Thursday the UK's Medicines and Healthcare Products Regulatory Agency granted an Innovation Passport designation for its MM120 orally disintegrated table, which is currently in clinical development for the treatment of generalized anxiety disorder.

The designation allows access to tools to support the design, development, and approvals process in the UK, and provides opportunities for enhanced regulatory and other stakeholder input, the biopharmaceutical company said.

The passport is considered an "entry point" to the Innovative Licensing and Access Pathway, a program that seeks to speed up patients' access to new medicines, the company said.

Shares of the Mind Medicine fell 3.6% in recent Thursday trading.

Price: 7.21, Change: -0.27, Percent Change: -3.61